Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jun 7, 2013; 19(21): 3309-3315
Published online Jun 7, 2013. doi: 10.3748/wjg.v19.i21.3309
Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer
Ying Wu, Zhe-Wei Wei, Yu-Long He, Roderich E Schwarz, David D Smith, Guang-Kai Xia, Chang-Hua Zhang
Ying Wu, Zhe-Wei Wei, Yu-Long He, Guang-Kai Xia, Chang-Hua Zhang, Department of Gastrointestinopancreatic Surgery of the First Affiliated Hospital of Sun Yat-Sen University, Gastric Cancer Center of Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China
Roderich E Schwarz, IU Health Goshen Center for Cancer Care, Indiana University, Goshen, IN 46526, United States
David D Smith, Division of Biostatistics, City of Hope National Medical Center, Duarte, CA 91010, United States
Author contributions: Wu Y and Wei ZW contributed equally to this work; He YL, Schwarz RE and Zhang CH designed the research; Wu Y, Wei ZW, Xia GK and Zhang CH performed the research; Wu Y, Wei ZW and Smith DD analyzed the data; Wu Y, Wei ZW and Zhang CH wrote the paper.
Supported by National Natural Science Foundation of China, No. 30700805 and 81272643; Project 5010 from Sun Yat-Sen University, No. 20100816; Young Teacher Training Project of Sun Yat-Sen University, No. 09ykpy49
Correspondence to: Chang-Hua Zhang, MD, PhD, Department of Gastrointestinopancreatic Surgery of the First Affiliated Hospital of Sun Yat-Sen University, Gastric Cancer Center of Sun Yat-Sen University, 58 Zhongshan 2nd Road, Guangzhou 510080, Guangdong Province, China. zhchangh@mail.sysu.edu.cn
Telephone: +86-20-87331059 Fax: +86-20-87331059
Received: January 30, 2013
Revised: April 16, 2013
Accepted: May 7, 2013
Published online: June 7, 2013
Processing time: 125 Days and 9.4 Hours
Core Tip

Core tip: This original study retrospectively analyzed the efficacy of adjuvant chemotherapy and compared the effects of adjuvant capecitabine and oxaliplatin (XELOX) therapy with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX6) therapy in gastric cancer patients undergoing D2 dissection. Propensity score matched-pair analysis was performed to account for biases associated with retrospective data. Adjuvant XELOX was significantly associated with improved survival after D2 dissection compared to surgery alone following multivariate Cox regression and propensity score matched analyses, however, the XELOX regimen did not result in a greater survival benefit compared with the FOLFOX6 regimen. Our findings suggest that adjuvant XELOX therapy should be considered in curable gastric cancer patients.